Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Novan, Inc. (NASDAQ: NOVN).

Full DD Report for NOVN

You must become a subscriber to view this report.


Recent News from (NASDAQ: NOVN)

Novan Announces Full Top Line Results from Phase 2 Molluscum Contagiosum Clinical Trial and Decision to Move Forward with SB206 12% Once-Daily
SB206 12% once-daily achieved the highest rate of complete clearance out of all active treatment groups at Week 12 (p<0.05) Statistically significant reductions in molluscum lesions as early as Week 2 with 12% once-daily No quantifiable levels of systemic exposure detected for S...
Source: GlobeNewswire
Date: December, 10 2018 07:30
Novan to Present at Piper Jaffray 30th Annual Healthcare Conference
MORRISVILLE, N.C., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that Paula Brown Stafford, Chief Development Officer, and Nathan Stasko, President and Chief Scientific Officer, are scheduled to participate in a fireside chat at the P...
Source: GlobeNewswire
Date: November, 20 2018 08:05
Novan Publication Supports Women's Health Business Unit Initiative and Nitric Oxide's Potential Against HPV-Associated Diseases
Data from SB206 Phase 2 clinical trial in external genital warts have been published in the Journal of Drugs in Dermatology SB206 was efficacious and well tolerated in the trial Advancement of the late stage clinical asset for external genital warts will be a priority for the recently...
Source: GlobeNewswire
Date: November, 01 2018 08:05
Novan Creates Dedicated Women's Health Business Unit
Business unit will focus on Novan’s proprietary nitric oxide technology and its application to target high-risk human papillomavirus (HPV) and associated cancers affecting women such as cervical cancer where 70% of cases have been conclusively linked to HPV Novan partners with He...
Source: GlobeNewswire
Date: October, 25 2018 07:05
Novan Extends Technical Production Capacity and Reaches Agreement with Orion Corporation
External manufacturing agreement reached to enable production of clinical trial materials for SB204 and the acne indication, with the potential to include additional product candidates Extension of capacity complements existing internal operations, proprietary technological knowledge,...
Source: GlobeNewswire
Date: October, 16 2018 08:05
Novan expands nitric oxide dermatology business partnership with Sato in Japan
Novan (NASDAQ: NOVN ) has expanded its partnership with Sato Pharmaceutical Co., to include Novan’s topical nitric oxide-releasing product candidate SB206 for the treatment of viral skin infections including warts and molluscum contagiosum. More news on: Novan, Healthcare sto...
Source: SeekingAlpha
Date: October, 08 2018 08:53
Novan Expands Nitric Oxide Dermatology Business Partnership with Sato in Japan
Expanded license agreement adds SB206 for the treatment of viral skin infections Novan to receive upfront cash consideration of approximately 1.25 billion JPY (~$11.0 million), payable over the next 12 months Milestone and royalty payments due with clinical, regulatory and commerc...
Source: GlobeNewswire
Date: October, 08 2018 08:00
Novan's Phase 2 Molluscum Contagiosum Trial Fully Enrolled: Top Line Results Targeted in November
Trial enrollment completed meaningfully ahead of schedule Top line results targeted to be communicated no later than mid-November Favorable and consistent safety profile of SB206 enabled escalation to highest, 12% dose MORRISVILLE, N.C., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Novan, Inc...
Source: GlobeNewswire
Date: October, 01 2018 08:05
Novan up 22% premarket on encouraging performance of SB414 2%
Thinly traded nano cap Novan (NASDAQ: NOVN ) is up  22%  premarket on light volume on the heels of its announcement of positive early-stage data on topical cream SB414. More news on: Novan, Healthcare stocks news, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: August, 20 2018 07:49
Novan Announces Promising Clinical Results with SB414
In the recently completed Phase 1b trial for atopic dermatitis, clinical efficacy measures were highly correlated with critical and disease-relevant biomarker changes suggesting a topical nitric oxide therapeutic has the potential to realize disease modification The combination of cli...
Source: GlobeNewswire
Date: August, 20 2018 06:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-141.381.27911.45991.25138,325
2018-12-131.501.401.501.3763,093
2018-12-121.501.491.541.45212,922
2018-12-111.281.501.58391.28220,621
2018-12-101.431.261.76141.23245,265

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-143,31537,0998.9356Cover
2018-12-139,89623,38442.3195Short
2018-12-1215,54146,66533.3033Cover
2018-12-1128,89971,30640.5281Short
2018-12-1018,45059,62930.9413Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on NOVN.


About Novan, Inc. (NASDAQ: NOVN)

Logo for Novan, Inc. (NASDAQ: NOVN)

Not available

 

Contact Information

 

 

Current Management

  • Jeff N Hunter / EVP, CBO
  • Andrew J. Novak / Vice President, Chief Accounting Officer, Principal Acct. Officer
    • Mr. Novak, age , has served as the Company s Director of Financial Reporting and Analysis since June and Senior Director of Financial Reporting and Analysis since March . From June until March , Mr. Novak served as Director of Financial and SEC Reporting for Scynexis, Inc., a biotechnology company. Prior to joining Scynexis, Inc., Mr. Novak served as an Audit Manager at Deloitte amp Touche from September to October and as a Technical Manager, Accounting amp Audit Publications for the American Institute of Certified Public Accountants from October to June . Mr. Novak is a certified public accountant and holds both a Bachelor of Science in Business Administration, Finance and a Master of Science in Accountancy from the University of North Carolina at Wilmington.

Current Share Structure

  • Market Cap: $81,761,650 - 05/11/2018
  • Issue and Outstanding: 26,038,742 - 03/23/2018

 


Recent Filings from (NASDAQ: NOVN)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 15 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: May, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 18 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 18 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 18 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 17 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 27 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 21 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018

 

 


Daily Technical Chart for (NASDAQ: NOVN)

Daily Technical Chart for (NASDAQ: NOVN)


Stay tuned for daily updates and more on (NASDAQ: NOVN)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: NOVN)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in NOVN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of NOVN and does not buy, sell, or trade any shares of NOVN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/